2Zhou ZX,Li D,Guan SS,et al.Immunotherapeutic effects of dendritic cells pulsed with a coden-optimized hpv 16 e6 and e7 fusion gene in vivo and in vitro [J] .Asian Pac J Cancer Prev,2015,16(9):3843-3847.
4Tsai HJ.Clinical cancer chemoprevention:From the hepatitis b virus(hbv)vaccine to the human papillomavirus(hpv)vaccine [J] .Taiwan J Obstet Gynecol,2015,54(2): 112-115.
5Nardelli-Haefliger D,Wirthner D,Schiller JT, et al.Specific antibody levels at the cervical during the menstrual cycle of women vaccinated with human papillomavirus 16 viruslike particles[J] .J Natl Cancer Inst,2003,95(15): 1128-1137.
6Riethmuller D,Jacquard AC,Lacau St Guily J,et al.Potential impact of a nonavalent hpv vaccine on the occurrence of hpv-related diseases in france [J] .BMC Public Health,2015,15(1):453.
3zur Hausen H. Papillomaviruscs and cancer:from basic study to clinical application. Nat Rev Cancer, 2002, 2:342-350
4Bao Y P, Li N, Smith J S, et al. Human papillomavirus type-distribution in women from asia: A Meta-analysis. Int J Gynecol Cancer, 2007, 17:1-9
5Zhou J, Sun X Y, Stenzel D J, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial ceils is sufficient for assembly of HPV virion-like particles. Virology, 1991, 185:251-257
6Govan V A. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther Clin Risk Manag, 2008, 4(1): 65-70
7Heymann W R. The human papillomavirus vaccine. J Am Acad Dermatol, 2008, 58(6): 1047- 1048
8Keam S J, Harper D M. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix], Drugs, 2008, 68(3): 359-372
9Kirnbauer R, Schellenbacher C, Shafti-Keramat S, et al. HPV infections of the oral and genital mucosa. Possibilities for primary prevention[J]. Hautarzt, 2009, 60(11): 878-880.
10Mougin C, Bourgault-Villada I, Coursaget P. HPV immunization for the prevention of cervical cancer[J]. Presse Med, 2009, 38 (12): 1750-1768.
